Leerink Partners Reiterates Market Perform Rating for iTeos Therapeutics (NASDAQ:ITOS)

iTeos Therapeutics (NASDAQ:ITOS)‘s stock had its “market perform” rating reissued by research analysts at Leerink Partners in a research note issued on Wednesday,Benzinga reports. They presently have a $9.00 price target on the stock, down from their previous price target of $47.00. Leerink Partners’ price objective points to a potential upside of 14.65% from the company’s current price.

ITOS has been the subject of a number of other research reports. HC Wainwright reissued a “buy” rating and set a $46.00 target price on shares of iTeos Therapeutics in a report on Thursday, March 6th. Wedbush reissued an “outperform” rating and issued a $25.00 price objective on shares of iTeos Therapeutics in a research note on Wednesday, March 5th. JPMorgan Chase & Co. cut shares of iTeos Therapeutics from an “overweight” rating to a “neutral” rating and lowered their target price for the stock from $15.00 to $8.00 in a research note on Tuesday. Finally, Wells Fargo & Company decreased their price target on shares of iTeos Therapeutics from $17.00 to $16.00 and set an “overweight” rating on the stock in a research note on Tuesday, April 29th. Two equities research analysts have rated the stock with a hold rating and three have given a buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $20.80.

iTeos Therapeutics Stock Performance

iTeos Therapeutics stock opened at $7.85 on Wednesday. The stock has a market capitalization of $300.45 million, a P/E ratio of -2.49 and a beta of 1.39. The company’s fifty day moving average price is $6.56 and its 200 day moving average price is $7.43. iTeos Therapeutics has a 1 year low of $4.80 and a 1 year high of $18.70.

iTeos Therapeutics (NASDAQ:ITOS) last released its earnings results on Monday, April 28th. The company reported ($0.80) EPS for the quarter, topping analysts’ consensus estimates of ($0.94) by $0.14. Sell-side analysts predict that iTeos Therapeutics will post -3.49 EPS for the current year.

Institutional Trading of iTeos Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the stock. JPMorgan Chase & Co. boosted its position in shares of iTeos Therapeutics by 1.2% during the 3rd quarter. JPMorgan Chase & Co. now owns 467,319 shares of the company’s stock valued at $4,771,000 after acquiring an additional 5,368 shares during the last quarter. Marquette Asset Management LLC acquired a new position in iTeos Therapeutics in the 4th quarter valued at about $122,000. Clear Harbor Asset Management LLC purchased a new stake in shares of iTeos Therapeutics in the 4th quarter valued at approximately $96,000. SG Americas Securities LLC grew its stake in shares of iTeos Therapeutics by 12.2% in the 4th quarter. SG Americas Securities LLC now owns 13,866 shares of the company’s stock valued at $106,000 after buying an additional 1,508 shares during the period. Finally, Empowered Funds LLC increased its holdings in shares of iTeos Therapeutics by 5.0% during the 4th quarter. Empowered Funds LLC now owns 69,072 shares of the company’s stock worth $530,000 after buying an additional 3,305 shares during the last quarter. 97.16% of the stock is owned by institutional investors and hedge funds.

iTeos Therapeutics Company Profile

iTeos Therapeutics, Inc is a clinical-stage biopharmaceutical company, which engages in the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes EOS-448, Inupadenant, and EOS-984. The company was founded by Michel Detheux in April 2012 and is headquartered in Watertown, MA.